Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Conditions
- Myeloid Malignancies
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT04778410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04718376
- Locations
- 🇨🇳
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Harbin Medical University Hospital, Harbin, Heilongjiang, China
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma
- Conditions
- Advanced Gastric Carcinoma
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT04718402
- Locations
- 🇨🇳
Hebei General Hospital, Shijiazhuang, Hebei, China
🇨🇳Beijing Luhe Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04719065
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 190
- Registration Number
- NCT04668690
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Undifferentiated Leukemia
- Interventions
- Procedure: Hematopoietic Cell TransplantationRadiation: Total-Body IrradiationProcedure: Multigated Acquisition ScanProcedure: EchocardiographyProcedure: X-Ray ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04375631
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT04352413
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04331743
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyOther: Fludeoxyglucose F-18Drug: Liposome-encapsulated Daunorubicin-CytarabineProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Questionnaire Administration
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1186
- Registration Number
- NCT04293562
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
- Conditions
- Myeloid NeoplasmAcute Myeloid Leukemia
- Interventions
- Drug: Liposome-encapsulated Daunorubicin-CytarabineOther: Questionnaire AdministrationBiological: Recombinant Granulocyte Colony-Stimulating FactorOther: Quality-of-Life Assessment
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04195945
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.